Moderna, Inc. vs Pharmacyclics
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Moderna, Inc. had more revenue: $1.9 B in the year to December 2025 against $730 M for Pharmacyclics in the year to December 2014.
- Pharmacyclics made a net profit of $86 M, while Moderna, Inc. made a net loss of $2.8 B.
- Pharmacyclics keeps more of each dollar of sales: a net margin of 11.8% against -145.2% for Moderna, Inc.
Market cap history
● Moderna, Inc.● Pharmacyclics
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Moderna, Inc. MRNA · #275 in the world | Pharmacyclics PCYC |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | 2010 | 1991 |
| Size | ||
| Market cap | $90.1 B | — |
| Revenue | $1.9 B | $730 M |
| Net income | $-2.8 B | $86 M▲ best |
| Employees | 4,700 | — |
| Valuation | ||
| Price to sales | 35.7× | — |
| Price to book | 10.4× | — |
| Free cash flow yield | -2.3% | — |
| Profitability | ||
| Gross margin | 55.4% | — |
| Operating margin | -158.1% | — |
| Net margin | -145.2% | — |
| Return on equity | -28.9% | — |
| Growth | ||
| Revenue growth | -39.9% | — |
| Revenue growth, 3 years a year | -53.4% | — |
| Financial strength | ||
| Debt to equity | 0.1× | — |
| Cash | ||
| Free cash flow margin | -106.2% | — |
| Shareholder returns | ||
| Shareholder yield | 0.0% | — |
| Strength scores | ||
| Piotroski F-score | 3 of 9 | — |
| Altman Z-score zone | safe | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap — |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which makes more money, Moderna, Inc. or Pharmacyclics?
Moderna, Inc. had more revenue: $1.9 B in the year to December 2025 against $730 M for Pharmacyclics in the year to December 2014. Pharmacyclics made a net profit of $86 M, while Moderna, Inc. made a net loss of $2.8 B.
Which is more profitable, Moderna, Inc. or Pharmacyclics?
Pharmacyclics keeps more of each dollar of sales: a net margin of 11.8% against -145.2% for Moderna, Inc.
More about Moderna, Inc.
More about Pharmacyclics
Sources#
Every figure on this page comes from these, with the date shown next to it.